144 related articles for article (PubMed ID: 31697256)
1. Predictive value of the bone markers osteocalcin and C-terminal telopeptide for jaw osteonecrosis in high-risk prostate cancer patients on bisphosphonate therapy: A prospective study.
Delaka A; Mourmouras N; Zervou-Valvi F; Stravodimos K; Anastasiou I; Delakas D
Arch Esp Urol; 2019 Nov; 72(9):948-954. PubMed ID: 31697256
[TBL] [Abstract][Full Text] [Related]
2. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
3. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates.
Kim JW; Kong KA; Kim SJ; Choi SK; Cha IH; Kim MR
Bone; 2013 Nov; 57(1):201-5. PubMed ID: 23954759
[TBL] [Abstract][Full Text] [Related]
4. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?
O'Connell JE; Ikeagwani O; Kearns GJ
Ir J Med Sci; 2012 Jun; 181(2):237-42. PubMed ID: 22223192
[TBL] [Abstract][Full Text] [Related]
5. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw.
Peisker A; Raschke GF; Fahmy MD; Guentsch A; Roshanghias K; König KC; Schultze-Mosgau S
J Craniofac Surg; 2018 Mar; 29(2):e137-e140. PubMed ID: 29215447
[TBL] [Abstract][Full Text] [Related]
6. Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.
Thumbigere-Math V; Michalowicz BS; Hughes PJ; Basi DL; Tsai ML; Swenson KK; Rockwell L; Gopalakrishnan R
J Oral Maxillofac Surg; 2016 Apr; 74(4):738-46. PubMed ID: 26501428
[TBL] [Abstract][Full Text] [Related]
7. C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases.
Pasoff M
J Can Dent Assoc; 2013; 79():d51. PubMed ID: 23920073
[TBL] [Abstract][Full Text] [Related]
8. Experimental investigation of relationship between trauma and bisphosphonate-related osteonecrosis.
Agaçayak KS; Yuksel H; Atilgan S; Koparal M; Uçan MC; Ozgöz M; Yaman F; Atalay Y; Acikan I
Niger J Clin Pract; 2014; 17(5):559-64. PubMed ID: 25244263
[TBL] [Abstract][Full Text] [Related]
9. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws.
Kwon YD; Lee DW; Choi BJ; Lee JW; Kim DY
Osteoporos Int; 2012 Nov; 23(11):2721-5. PubMed ID: 22218418
[TBL] [Abstract][Full Text] [Related]
10. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers.
Fleisher KE; Welch G; Kottal S; Craig RG; Saxena D; Glickman RS
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):509-16. PubMed ID: 20674404
[TBL] [Abstract][Full Text] [Related]
11. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
12. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
[TBL] [Abstract][Full Text] [Related]
13. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?
Atalay B; Yalcin S; Emes Y; Aktas I; Aybar B; Issever H; Mandel NM; Cetin O; Oncu B
Lasers Med Sci; 2011 Nov; 26(6):815-23. PubMed ID: 21809068
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review.
Dal Prá KJ; Lemos CA; Okamoto R; Soubhia AM; Pellizzer EP
Int J Oral Maxillofac Surg; 2017 Feb; 46(2):151-156. PubMed ID: 27876532
[TBL] [Abstract][Full Text] [Related]
16. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.
Awad ME; Sun C; Jernigan J; Elsalanty M
J Am Dent Assoc; 2019 Aug; 150(8):664-675.e8. PubMed ID: 31256803
[TBL] [Abstract][Full Text] [Related]
17. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
Kwon YD; Ohe JY; Kim DY; Chung DJ; Park YD
Clin Oral Implants Res; 2011 Jan; 22(1):100-5. PubMed ID: 20946206
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
J Oral Maxillofac Surg; 2009 Jan; 67(1):159-61. PubMed ID: 19070762
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
